CBL — Control Bionics Income Statement
0.000.00%
Last trade - 00:00
- AU$6.23m
- AU$4.99m
- AU$5.91m
- 36
- 64
- 29
- 42
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.901 | 3.3 | 4.09 | 4.72 | 5.91 |
Cost of Revenue | |||||
Gross Profit | 0.556 | 2.59 | 2.66 | 2.74 | 3.98 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.83 | 4.3 | 7.67 | 10.8 | 11.5 |
Operating Profit | -1.93 | -1 | -3.58 | -6.08 | -5.61 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.93 | -1.01 | -3.55 | -6.1 | -5.63 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.93 | -1.01 | -3.55 | -6.1 | -5.63 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.93 | -1.01 | -3.55 | -6.1 | -5.63 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.93 | -1.01 | -3.55 | -6.1 | -5.63 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.021 | -0.011 | -0.045 | -0.065 | -0.052 |
Dividends per Share |